GeneDx Holdings Corp. WGS
55.12 USD 0.00 (+0.00%)
At closeNov 12, 2026, 8:09 AM EST
54.99 -0.13 -0.24%
Pre-market · Nov 12, 8:09 AM ET
Day range unavailable
32.21 52-week range 170.87
- YTD
- -57.62%
- 1 year
- -59.60%
News
businesswire.com GeneDx to Participate in Upcoming Investor Conferences GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.
fool.com Why GeneDx Holdings Stock Just Dropped 16.6% GeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations. Sales rose 5% to $123.1 million, in line with estimates,…
schaeffersresearch.com 4 Post-Earnings Losers Drawing Unusual Options Volume Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and…
benzinga.com GeneDx To Present New Research At The National Society Of Genetic Counselors Conference, November 11-14; Data Show 62% Of Patients With Pathogenic Or Likely Pathogenic Findings Had Results Associated With Opportunities To Inform Medical Management New research analyzing exome and genome sequencing results from more than 300,000 patients found that 62% of patients with pathogenic or likely pathogenic findings (62,459 of 101,390) had results…
businesswire.com GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients.
benzinga.com Groupon Posts Downbeat Q3 Results, Joins GeneDx Holdings, Qualys And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session Groupon plunged 20% premarket after missing quarterly earnings and sales estimates, while Digital Turbine, Daqo and others also traded lower.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…
benzinga.com Why Sanmina Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket Sanmina surges 18.8% after strong Q4 results and above-estimate FY27 guidance; Rubico leads gainers, while Microvast plunges 48.5%.
benzinga.com BTIG Maintains Buy on GeneDx Holdings, Lowers Price Target to $85 BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $90 to $85.
seekingalpha.com GeneDx Holdings Corp. (WGS) Q3 2026 Earnings Call Transcript GeneDx Holdings Corp. ( WGS ) Q3 2026 Earnings Call November 9, 2026 4:30 PM EST Company Participants Sabrina Dunbar - Director of Investor Relations & Communications Katherine Stueland - CEO &…
seekingalpha.com GeneDx: Q3 Earnings Indicate Transition To Sustained Profitability GeneDx Holdings is transitioning to sustained profitability, with strong revenue growth expected through 2027. WGS beat revenue estimates for Q3 but fell short on EPS estimates. Key strategies…
marketbeat.com GeneDx Q3 Earnings Call Highlights GeneDx NASDAQ: WGS reported third-quarter revenue of $123.1 million and raised its full-year profitability outlook, even as new documentation requirements led the genetic testing company to lower its…
zacks.com GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.49 per share a year ago.
benzinga.com GeneDx Holdings Q3 2026 Earnings Call Transcript GeneDx Holdings (NASDAQ:WGS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $482.324M Est GeneDx Holdings (NASDAQ:WGS) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $482.324 million estimate.
businesswire.com GeneDx Reports Third Quarter 2026 Financial Results GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2026.
businesswire.com GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com GeneDx Plans To Enhance Its Genome Testing Portfolio With Long-Read Whole Genome Sequencing Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com GeneDx To Present New Results At International Consortium On Newborn Sequencing For Its Genomic Newborn Screening GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new findings to be presented at the International Consortium on…- benzinga.com Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83 Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $74 to $83.
- benzinga.com GeneDx Partners With Beren Therapeutics To Launch The NPC GenomeComplete Sponsored Testing Program For Niemann-Pick Disease Type C The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C…
benzinga.com Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside Ondas, SoundHound AI and CleanSpark are in the top ten most-heavily shorted stocks in the market right now.
benzinga.com GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric Care Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosisChildren experiencing…
benzinga.com Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90 Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.- benzinga.com CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate GeneDx Hldgs (NASDAQ:WGS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.19) by 105.26 percent. This is a 98 percent decrease over earnings of $0.50…
- benzinga.com GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est GeneDx Holdings (NASDAQ:WGS) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $478.367 million estimate.
- benzinga.com Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74 Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $70 to $74.
- benzinga.com Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63 Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.
- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Why Is GeneDx Stock Surging Thursday? GeneDx (WGS) shares rebound 12% as bargain hunters move in following a steep post-earnings sell-off. Is the genetic testing leader oversold?- benzinga.com Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75 Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.
benzinga.com Crude Oil Down 4%; PayPal Shares Fall After Q1 Results US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.- benzinga.com Wells Fargo Maintains Overweight on GeneDx Holdings, Lowers Price Target to $75 Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and lowers the price target from $155 to $75.
- benzinga.com Guggenheim Maintains Buy on GeneDx Holdings, Lowers Price Target to $70 Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $70.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance. Other stocks falling in pre-market trading.- benzinga.com BTIG Maintains Buy on GeneDx Holdings, Lowers Price Target to $90 BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $170 to $90.
benzinga.com Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after reporting better-than-expected Q1 results and raising its FY26 guidance. Other gainers include BLZE,…- benzinga.com CORRECTION: GeneDx Hldgs Q1 Adj. EPS $(0.28) Misses $(0.01) Estimate, Sales $102.300M Miss $112.956M Estimate GeneDx Hldgs (NASDAQ:WGS) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.01) by 2700 percent. This is a 203.7 percent decrease over earnings of…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com GeneDx Holdings Lowers FY2026 Sales Guidance from $540.000M-$555.000M to $475.000M-$490.000M vs $550.216M Est GeneDx Holdings (NASDAQ:WGS) lowers FY2026 sales outlook from $540.000 million-$555.000 million to $475.000 million-$490.000 million vs $550.216 million estimate.
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Guggenheim Maintains Buy on GeneDx Holdings, Lowers Price Target to $100 Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $170 to $100.
- benzinga.com Earnings Scheduled For February 23, 2026